IMAB vs. EDIT, AURA, CCCC, CYRX, ESPR, TSHA, ORGO, NLTX, ANRO, and URGN
Should you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include Editas Medicine (EDIT), Aura Biosciences (AURA), C4 Therapeutics (CCCC), Cryoport (CYRX), Esperion Therapeutics (ESPR), Taysha Gene Therapies (TSHA), Organogenesis (ORGO), Neoleukin Therapeutics (NLTX), Alto Neuroscience (ANRO), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry.
Editas Medicine (NASDAQ:EDIT) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability.
I-Mab has a net margin of 0.00% compared to I-Mab's net margin of -239.36%. Editas Medicine's return on equity of 0.00% beat I-Mab's return on equity.
Editas Medicine has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.
In the previous week, Editas Medicine had 8 more articles in the media than I-Mab. MarketBeat recorded 9 mentions for Editas Medicine and 1 mentions for I-Mab. Editas Medicine's average media sentiment score of 1.89 beat I-Mab's score of 0.78 indicating that I-Mab is being referred to more favorably in the news media.
Editas Medicine has higher revenue and earnings than I-Mab.
Editas Medicine received 246 more outperform votes than I-Mab when rated by MarketBeat users. However, 62.92% of users gave I-Mab an outperform vote while only 53.64% of users gave Editas Medicine an outperform vote.
Editas Medicine presently has a consensus price target of $12.90, indicating a potential upside of 128.32%. I-Mab has a consensus price target of $12.25, indicating a potential upside of 800.74%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts clearly believe I-Mab is more favorable than Editas Medicine.
71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 1.9% of Editas Medicine shares are owned by company insiders. Comparatively, 22.1% of I-Mab shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
I-Mab beats Editas Medicine on 9 of the 15 factors compared between the two stocks.
Get I-Mab News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
